PMID- 30305865
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20211204
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2018
DP  - 2018
TI  - Emerging Role of mTOR Signaling-Related miRNAs in Cardiovascular Diseases.
PG  - 6141902
LID - 10.1155/2018/6141902 [doi]
LID - 6141902
AB  - Mechanistic/mammalian target of rapamycin (mTOR), an atypical serine/threonine 
      kinase of the phosphoinositide 3-kinase- (PI3K-) related kinase family, elicits a 
      vital role in diverse cellular processes, including cellular growth, 
      proliferation, survival, protein synthesis, autophagy, and metabolism. In the 
      cardiovascular system, the mTOR signaling pathway integrates both intracellular 
      and extracellular signals and serves as a central regulator of both physiological 
      and pathological processes. MicroRNAs (miRs), a class of short noncoding RNA, are 
      an emerging intricate posttranscriptional modulator of critical gene expression 
      for the development and maintenance of homeostasis across a wide array of 
      tissues, including the cardiovascular system. Over the last decade, numerous 
      studies have revealed an interplay between miRNAs and the mTOR signaling circuit 
      in the different cardiovascular pathophysiology, like myocardial infarction, 
      hypertrophy, fibrosis, heart failure, arrhythmia, inflammation, and 
      atherosclerosis. In this review, we provide a comprehensive state of the current 
      knowledge regarding the mechanisms of interactions between the mTOR signaling 
      pathway and miRs. We have also highlighted the latest advances on mTOR-targeted 
      therapy in clinical trials and the new perspective therapeutic strategies with 
      mTOR-targeting miRs in cardiovascular diseases.
FAU - Samidurai, Arun
AU  - Samidurai A
AUID- ORCID: 0000-0002-5360-2553
AD  - Pauley Heart Center, Department of Internal Medicine, Division of Cardiology, 
      Virginia Commonwealth University, Richmond, VA 23298, USA.
FAU - Kukreja, Rakesh C
AU  - Kukreja RC
AD  - Pauley Heart Center, Department of Internal Medicine, Division of Cardiology, 
      Virginia Commonwealth University, Richmond, VA 23298, USA.
FAU - Das, Anindita
AU  - Das A
AUID- ORCID: 0000-0003-4422-7277
AD  - Pauley Heart Center, Department of Internal Medicine, Division of Cardiology, 
      Virginia Commonwealth University, Richmond, VA 23298, USA.
LA  - eng
GR  - R01 HL118808/HL/NHLBI NIH HHS/United States
GR  - R01 HL134366/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20180823
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (MicroRNAs)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/genetics/*metabolism
MH  - Humans
MH  - MicroRNAs/genetics/*metabolism
MH  - Signal Transduction/*physiology
MH  - TOR Serine-Threonine Kinases/genetics/*metabolism
PMC - PMC6165581
EDAT- 2018/10/12 06:00
MHDA- 2018/12/12 06:00
PMCR- 2018/08/23
CRDT- 2018/10/12 06:00
PHST- 2018/05/05 00:00 [received]
PHST- 2018/07/04 00:00 [accepted]
PHST- 2018/10/12 06:00 [entrez]
PHST- 2018/10/12 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2018/08/23 00:00 [pmc-release]
AID - 10.1155/2018/6141902 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2018 Aug 23;2018:6141902. doi: 10.1155/2018/6141902. 
      eCollection 2018.